Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Jun 28, 2022

—Covers Use of CM-101 and Sequence-Related Antibodies for the Treatment of Liver Diseases— —Extends Protections Afforded by Composition of Matter and Methods and Use Patents that Have Issued...

Jun 27, 2022

—Data Presented at 2022 EASL International Liver ConferenceTM and First International Extracellular Matrix Pharmacology Congress— TEL AVIV, Israel, June 27, 2022 /PRNewswire/ -- Chemomab...

Jun 21, 2022

—Ms. Quigley's Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs— TEL AVIV, Israel, June 21, 2022 /PRNewswire/ --...

Jun 9, 2022

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

All News

Stock Info
Thursday, June 23, 2022
4:45pm CEST

Congress information
Oral presentation
Session: Immune-mediated and cholestatic:
Experimental and pathophysiology

Thursday, June 23, 2022
1:00pm - 2:15pm CEST

Congress Information
Poster presentation
Poster Session 1

All Events

Featured Presentations


Chemomab Corporate Overview - June 2022


Annual Report


Chemomab 2021 Annual Report